Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Leukemia, Myeloid, Acute × GRN163L peptide × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Prolymphocytic, T-Cell 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Breast Neoplasms 1

Interventions

Cytarabine 133 Azacitidine 86 venetoclax 82 Cyclophosphamide 62 fludarabine 60 Decitabine 55 fludarabine phosphate 51 Filgrastim 32 Daunorubicin 31 Specimen Handling 29 Idarubicin 26 Mitoxantrone 25 Etoposide 24 Injections 21 Clofarabine 21 Granulocyte Colony-Stimulating Factor 20 Tacrolimus 18 Busulfan 18 Biopsy 17 Peripheral Blood Stem Cell Transplantation 16 Methotrexate 16 Melphalan 16 Whole-Body Irradiation 15 Vorinostat 15 Mycophenolic Acid 15 Gemtuzumab 15 Bortezomib 15 Lenalidomide 13 Stem Cell Transplantation 12 Sorafenib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07320235 2026-01-06

IMAGINE

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡